Ultralife
Ultralife's revenue rose 16.2% to $191 million in fiscal 2025. Its operating margin was −3.1%, down from 6.1% a year earlier. Free cash flow was $7 million, down 51.6%. The diluted share count fell 0.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2016 to 2023, earnings per share grew 9.7% a year and net income 10.9% a year, as new shares raised the share count by 5% and diluted each share's earnings. Ultralife then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 8 | 6 | 10 | 7 | 9 |
| Debt incl. finance leases | 21 | 22 | 26 | 55 | 50 |
| Net debt (negative means net cash) | 13 | 16 | 16 | 48 | 40 |
| Net debt to EBITDA | 3.5x | 3.5x | 1.2x | 3.4x | — |
| Debt to equity | 0.2x | 0.2x | 0.2x | 0.4x | 0.4x |
| Interest coverage | 0.1x | 0.1x | 4.7x | 5.1x | −1.5x |
| Current ratio | 3.5x | 2.7x | 3.8x | 3.3x | 2.8x |
| Quick ratio | 1.8x | 1.3x | 2.0x | 1.6x | 1.4x |
Cash flow
Projections
Project Ultralife's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $2.3 million of Ultralife shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 26, 2026 | Bradford T WhitmoreDirector, 10% owner | Bought | 67,302 | $6.81 | $458,327 | Form 4 |
| May 22, 2026 | Bradford T WhitmoreDirector, 10% owner | Bought | 8,700 | $6.33 | $55,071 | Form 4 |
| May 21, 2026 | Bradford T WhitmoreDirector, 10% owner | Bought | 32,876 | $6.13 | $201,530 | Form 4 |
| May 18, 2026 | Michael Edward MannaPresident and CEO, Director | Bought | 2,000 | $6.47 | $12,940 | Form 4 |
| Mar 16, 2026 | Bradford T WhitmoreDirector, 10% owner | Bought | 53,131 | $6.76 | $359,166 | Form 4 |
| Mar 13, 2026 | Bradford T WhitmoreDirector, 10% owner | Bought | 100,640 | $6.32 | $636,045 | Form 4 |
| Mar 12, 2026 | Bradford T WhitmoreDirector, 10% owner | Bought | 33,741 | $5.97 | $201,434 | Form 4 |
| Mar 12, 2026 | Michael Edward MannaPresident and CEO, Director | Bought | 2,000 | $6.01 | $12,024 | Form 4 |
| Dec 16, 2025 | Bradford T WhitmoreDirector, 10% owner | Bought | 28,588 | $5.70 | $162,952 | Form 4 |
| Dec 15, 2025 | Bradford T WhitmoreDirector, 10% owner | Bought | 14,882 | $5.66 | $84,232 | Form 4 |
| Dec 15, 2025 | Janie GoddardDirector | Bought | 1,739 | $5.75 | $9,999 | Form 4 |
| Dec 12, 2025 | Bradford T WhitmoreDirector, 10% owner | Bought | 9,530 | $5.63 | $53,654 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 4 of 9 | 4 of 9 |
| Rule of 40 | 19.9% | 12.6% | 20.0% |
| Altman Z'' | 4.55 | 3.45 | 2.86 |
| Accruals ratio | 3.0% | −5.2% | −7.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 6 of 9 | 4 of 9 | 4 of 9 |
Compare
Put Ultralife side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ultralife | FY25 | 16.2% | −3.1% | 3.7% | −2.6% | — | 4 | |
| Energy Vault | FY25 | 340.9% | −36.5% | −22.9% | −58.8% | — | 3 | Compare |
| FuelCell Energy | FY25 | 41.0% | −121.6% | −91.0% | — | — | 5 | Compare |
| American Superconductor | FY26 | 34.3% | 3.8% | 6.1% | 4.3% | −7.5x | 6 | Compare |
| SunPower | FY25 | 175.9% | −9.0% | — | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 82 | 86 | 87 | 107 | 108 | 98 | 132 | 159 | 164 | 191 |
| Revenue growth | 7.9% | 3.7% | 1.9% | 22.5% | 0.9% | −8.8% | 34.2% | 20.3% | 3.7% | 16.2% |
| Gross profit | 25 | 26 | 26 | 31 | 29 | 25 | 29 | 39 | 42 | 46 |
| Research and development | 6 | 5 | 4 | 7 | 6 | 7 | 7 | 8 | 8 | 10 |
| Operating income | 4 | 6 | 7 | 7 | 6 | 0 | 0 | 10 | 10 | −6 |
| Net income | 4 | 8 | 25 | 5 | 5 | −0 | −0 | 7 | 6 | −6 |
| Diluted EPS (US$) | 0.23 | 0.48 | 1.53 | — | 0.33 | 0.05 | 0.05 | 0.44 | — | — |
| Diluted shares (millions) | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 17 | 17 |
| Cash flow | ||||||||||
| Cash from operations | 8 | 7 | 11 | −3 | 22 | 4 | −1 | 2 | 17 | 11 |
| Capital expenditure | 1 | 1 | 4 | 6 | 3 | 3 | 2 | 3 | 2 | 4 |
| Free cash flow | 6 | 6 | 7 | −9 | 19 | 2 | −3 | −1 | 15 | 7 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 10 | 0 | 0 | 25 | 0 | 24 | 0 | 0 | 48 | 0 |
| Stock-based compensation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 11 | 18 | 26 | 7 | 11 | 8 | 6 | 10 | 7 | 9 |
| Debt incl. finance leases | — | — | — | 17 | 1 | 21 | 22 | 26 | 55 | 50 |
| Total assets | 85 | 97 | 121 | 145 | 138 | 160 | 168 | 178 | 220 | 217 |
| Total liabilities | 17 | 18 | 16 | 35 | 21 | 42 | 52 | 53 | 86 | 87 |
| Shareholders' equity | 68 | 79 | 104 | 110 | 117 | 118 | 116 | 125 | 134 | 130 |
| Margins and ratios | ||||||||||
| Gross margin | 30.4% | 30.7% | 29.3% | 29.2% | 27.1% | 25.1% | 22.3% | 24.7% | 25.7% | 24.1% |
| Operating margin | 4.6% | 7.6% | 7.5% | 6.9% | 5.3% | 0.0% | 0.1% | 6.0% | 6.1% | −3.1% |
| Net margin | 4.3% | 8.9% | 28.6% | 4.9% | 4.9% | −0.2% | −0.1% | 4.5% | 3.8% | −3.1% |
| Free cash flow margin | 7.8% | 6.9% | 7.7% | −8.7% | 17.3% | 1.5% | −2.2% | −0.4% | 8.9% | 3.7% |
| Rule of 40 (growth + FCF margin) | 15.7% | 10.6% | 9.6% | 13.8% | 18.1% | −7.2% | 31.9% | 19.9% | 12.6% | 20.0% |
| Return on capital | — | — | — | — | 3.8% | 0.0% | 0.1% | 5.5% | 4.8% | −2.6% |
| Return on equity | 5.2% | 10.4% | 27.1% | 4.9% | 4.6% | −0.2% | −0.1% | 6.0% | 4.9% | −4.5% |
| Return on assets | 4.2% | 8.4% | 22.9% | 3.9% | 3.7% | −0.2% | −0.1% | 4.2% | 3.2% | −2.7% |
| Net debt to EBITDA | — | — | — | 1.0x | −1.1x | 3.5x | 3.5x | 1.2x | 3.4x | — |